VENCLYXTO 100 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the Patient

Venclyxto 10mg film-coated tablets

Venclyxto 50mg film-coated tablets

Venclyxto 100mg film-coated tablets

venetoclax

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What is Venclyxto and what is it used for
2. What you need to know before you take Venclyxto
3. How to take Venclyxto
4. Possible side effects
5. Storing Venclyxto
6. Contents of the pack and other information

1. What is Venclyxto and what is it used for

What is Venclyxto

Venclyxto is a cancer medicine that contains the active substance venetoclax. It belongs to a group of medicines called “BCL-2 inhibitors”.

What is Venclyxto used for

Venclyxto is used to treat adults with:

• chronic lymphocytic leukaemia (CLL). You may receive Venclyxto alone or in combination with other medicines.
• acute myeloid leukaemia (AML). You will receive Venclyxto in combination with other medicines.

CLL is a type of cancer that affects a type of white blood cell called lymphocytes and lymph nodes. In CLL, lymphocytes multiply too quickly and live too long, so that there are too many of them in the blood.

AML is a type of cancer that affects a type of white blood cell called myeloid cells. In AML, myeloid cells multiply and grow very quickly in the bone marrow and in the blood, so that there are too many of them and not enough red blood cells in the blood.

How Venclyxto works

Venclyxto works by blocking a protein in the body called “BCL-2”. This protein is found in high amounts in some cancer cells and helps cancer cells to survive. Blocking this protein helps to destroy cancer cells and reduce their number. It also delays the worsening of the disease.

2. What you need to know before you take Venclyxto

Do not take Venclyxto if:

• you are allergic to the active substance venetoclax or any of the other ingredients of this medicine (listed in section 6).

• you have CLL and are taking any of the following medicines when you start treatment and during the gradual increase in dose (usually for 5 weeks). You must not take them because they can cause serious and potentially life-threatening side effects when taken with Venclyxto:
• • itraconazole, ketoconazole, posaconazole or voriconazole for fungal infections.
  • clarithromycin for bacterial infections.
  • ritonavir for HIV infection.

Once the dose of Venclyxto has been increased to the full standard dose, ask your doctor if you can start taking these medicines again.

• you are taking a herbal medicine called St. John’s Wort, used for depression. If you are not sure, talk to your doctor, pharmacist or nurse before taking Venclyxto.

It is important that you tell your doctor, pharmacist or nurse about all the medicines you are taking, including those that you have bought without a prescription, vitamins and herbal supplements. Your doctor may ask you to stop taking certain medicines when you start taking Venclyxto and during the first few days or weeks, during the increase in dose to the full standard dose.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you start taking Venclyxto if:

• you have any kidney problems, as this may increase the risk of a side effect called tumour lysis syndrome.
• you have liver problems, as this may increase the risk of side effects. Your doctor may need to reduce your dose of Venclyxto.
• you think you may have an infection or have had a long-lasting or repeated infection.
• you are due to have a vaccination.

If you are in any of these situations, or are not sure, talk to your doctor, pharmacist or nurse before taking this medicine.

Tumour Lysis Syndrome

Some people may have high levels of certain salts in the blood (such as potassium and uric acid) due to the rapid breakdown of cancer cells during treatment. This can cause changes in kidney function, an abnormal heart rhythm or seizures. This condition is called tumour lysis syndrome (TLS). The risk of TLS is highest in the first few days or weeks of treatment with Venclyxto, when the dose is being increased.

If you have CLL

Your doctor, pharmacist or nurse will do blood tests to check for TLS.

Before you start treatment with Venclyxto, your doctor will give you medicines to help prevent the build-up of uric acid in your body.

Drinking plenty of water, at least 1.5 to 2 litres a day, helps to remove the waste products of cancer cells from the blood through the urine and may reduce the risk of TLS (see section 3).

Tell your doctor, pharmacist or nurse immediately if you have any of the symptoms of TLS listed in section 4.

If you are at risk of TLS, you may receive treatment in hospital so that you can be given extra fluids through a vein if needed, have more frequent blood tests and be checked for side effects. This is to make sure that it is safe for you to continue taking this medicine.

If you have AML

You may receive treatment in hospital and your doctor or nurse will make sure that you have enough water or fluids, give you medicines to prevent the build-up of uric acid in your body and do blood tests before you start taking Venclyxto, while the dose is being increased and when you start taking the full dose.

Children and adolescents

Venclyxto must not be used in children and adolescents.

Other medicines and Venclyxto

Tell your doctor or pharmacist if you are taking any of the following medicines, as they may increase or decrease the amount of venetoclax in the blood:

• medicines for fungal infections - fluconazole, itraconazole, ketoconazole, posaconazole or voriconazole
• antibiotics for bacterial infections - ciprofloxacin, clarithromycin, erythromycin, nafcillin or rifampicin
• medicines to prevent seizures or to treat epilepsy - carbamazepine, phenytoin
• medicines for HIV infection - efavirenz, etravirine, ritonavir
• medicines to treat high blood pressure or angina - diltiazem, verapamil
• medicines to lower cholesterol levels in the blood - colestyramine, colestipol, colesevelam
• a medicine used to treat a lung condition called pulmonary arterial hypertension - bosentan
• a medicine to treat a sleep disorder (narcolepsy) called modafinil
• a herbal medicine called St. John’s Wort

Your doctor may need to change your dose of Venclyxto.

Tell your doctor if you are taking any of the following medicines, as Venclyxto may affect how they work:

• medicines that prevent blood clots, warfarin, dabigatran
• a medicine to treat heart problems, called digoxin
• a medicine to treat cancer, called everolimus
• a medicine to prevent organ rejection, called sirolimus
• medicines to lower cholesterol levels in the blood, called statins

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those obtained without a prescription, herbal medicines and supplements. This is because Venclyxto may affect how some medicines work and some medicines may affect how Venclyxto works.

Taking Venclyxto with food and drink

Do not take products containing grapefruit, Seville oranges (bitter oranges, often used in marmalade) or starfruit while you are taking Venclyxto - do not eat them, drink their juice or take supplements that may contain them. This is because they can increase the amount of venetoclax in the blood.

Pregnancy

• Do not become pregnant while you are taking this medicine. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
• Venclyxto must not be used during pregnancy. There is no information on the safety of venetoclax in pregnant women.

Contraception

• Women who are able to become pregnant must use a highly effective method of contraception during treatment and for at least 30 days after receiving Venclyxto to prevent pregnancy. If you are using hormonal contraceptives (the pill or devices), you must also use a barrier method of contraception (such as a condom) because the effect of hormonal contraceptives may be affected by Venclyxto.
• Tell your doctor immediately if you become pregnant while you are taking this medicine.

Breast-feeding

Do not breast-feed while you are taking this medicine. It is not known whether the active substance of Venclyxto passes into breast milk.

Fertility

Based on the results of animal studies, Venclyxto may cause male infertility (reduced or absent sperm count). This may affect your ability to father a child. Ask your doctor about sperm storage before you start treatment with Venclyxto.

Driving and using machines

After taking Venclyxto, you may feel tired or dizzy, which may affect your ability to drive and use tools or machines. If this happens, do not drive or use any tools or machines.

Venclyxto contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially “sodium-free”.

3. How to take Venclyxto

Always take this medicine exactly as your doctor, pharmacist or nurse has told you. If you are not sure, check with your doctor, pharmacist or nurse.

How much to take

If you have CLL

You will start treatment with Venclyxto at a low dose for 1 week. Your doctor will gradually increase the dose over the next 4 weeks to the full standard dose. During the first 4 weeks, you will receive a new pack each week.

• the initial dose is 20 mg (2 x 10 mg tablets) once a day for 7 days.
• the dose will be increased to 50 mg (1 x 50 mg tablet) once a day for 7 days.
• the dose will be increased to 100 mg (1 x 100 mg tablet) once a day for 7 days.
• the dose will be increased to 200 mg (2 x 100 mg tablets) once a day for 7 days.
• the dose will be increased to 400 mg (4 x 100 mg tablets) once a day for 7 days.

A dose adjustment may be necessary due to side effects. Your doctor will tell you what dose to take.

If you have AML

You will start treatment with Venclyxto at a lower dose. Your doctor will gradually increase the dose each day over the first 3 days. After 3 days, you will take the full standard dose. The dose (tablets) is taken once a day.

The following table shows the doses

Your doctor will give you Venclyxto in combination with another medicine (azacitidine or decitabine).

You will continue to take the full dose of Venclyxto until your AML worsens or you are no longer able to take Venclyxto due to serious side effects.

How to take Venclyxto

• take the tablets with a meal, approximately at the same time each day
• swallow the tablets whole with a glass of water
• do not chew, crush or break the tablets
• during the first few days or weeks of treatment when the dose is being increased, take the tablets in the morning to make it easier to monitor you with blood tests if needed.

If you vomit after taking Venclyxto, do not take an extra dose that day. Take your next dose at the usual time the next day. If you have problems taking this medicine, talk to your doctor.

Drink plenty of water

If you have CLL

It is very important that you drink plenty of water while you are taking Venclyxto during the first 5 weeks of treatment. This will help to remove the waste products of cancer cells from the blood through the urine.

You should start drinking at least 1.5 to 2 litres of water a day, 2 days before you start taking Venclyxto. You can also include non-caffeinated, non-alcoholic drinks in this amount, but do not drink grapefruit, Seville orange or starfruit juice. You should continue to drink at least 1.5 to 2 litres of water a day, 2 days before your dose is increased and on the day of the increase.

If your doctor thinks that you are at risk of TLS, you may receive treatment in hospital so that you can be given extra fluids through a vein if needed, have more frequent blood tests and be checked for side effects. This is to make sure that it is safe for you to continue taking this medicine.

If you have AML

It is very important that you drink plenty of water while you are taking Venclyxto, especially when you start treatment and when the dose is increased. Drinking water will help to remove the waste products of cancer cells from the blood through the urine. If you are in hospital, your doctor or nurse will give you fluids through a vein if needed to make sure that this happens.

If you take more Venclyxto than you should

If you take more Venclyxto than you should, talk to a doctor, pharmacist or nurse or go to hospital immediately. Take the medicine pack and this leaflet with you.

If you forget to take Venclyxto

• do not take a double dose to make up for a forgotten dose.

If you stop taking Venclyxto

Do not stop taking this medicine unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. This medicine may cause the following serious adverse effects:

Tumor Lysis Syndrome(frequent - may affect up to 1 in 10 people)

Stop taking Venclyxto and seek medical attention immediately if you notice any of the symptoms of TLS:

• fever or chills
• nausea or vomiting
• confusion
• difficulty breathing
• irregular heartbeat
• dark or cloudy urine
• unusual feeling of tiredness
• muscle pain or joint discomfort
• seizures or convulsions
• abdominal pain and distension

Decrease in White Blood Cell Count (Neutropenia) and Infections(very frequent - may affect more than 1 in 10 people)

Your doctor will check your blood cell count during treatment with Venclyxto. A decrease in white blood cells can increase the risk of infections. The signs may be fever, chills, weakness, or confusion, cough, pain, or burning sensation when urinating. Some infections, such as pneumonia or blood infection (sepsis), can be severe and life-threatening. Inform your doctor immediately if you have signs of infection during treatment with this medicine.

Tell your doctor if you notice any of the following adverse effects:

If you have CLL

Very Common(may affect more than 1 in 10 people)

• pneumonia
• upper respiratory tract infection (signs are nasal discharge, sore throat, or cough)
• diarrhea
• nausea or vomiting
• constipation
• fatigue

Also, the following may be observed in blood tests:

• decrease in red blood cell count
• decrease in white blood cell count called lymphocytes
• increase in potassium levels
• increase in a body electrolyte (an electrolyte) called phosphate
• decrease in calcium levels

Common(may affect up to 1 in 10 people)

• severe blood infection (sepsis)
• urinary tract infection
• decrease in white blood cell count with fever (febrile neutropenia)

Also, the following may be observed in blood tests:

• increase in creatinine levels
• increase in urea levels

If you have LMA

Very Common(may affect more than 1 in 10 people)

• feeling of nausea (nausea or vomiting)
• diarrhea
• mouth sores
• feeling of tiredness or weakness
• lung or blood infection
• loss of appetite
• joint pain
• dizziness or fainting
• headache
• difficulty breathing
• bleeding
• low blood pressure
• urinary tract infection
• weight loss
• abdominal pain

Blood tests may show:

• low platelet count (thrombocytopenia)
• low white blood cell count with fever (febrile neutropenia)
• low red blood cell count (anemia)
• high total bilirubin levels
• low potassium levels in blood

Common(may affect up to 1 in 10 people)

• gallstones or gallbladder infection

Reporting Adverse Effects

If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system listed in Annex V. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Venclyxto

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the blister label and carton, after EXP.:

No special storage conditions are required.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Package Contents and Additional Information

Venclyxto Composition

The active substance is venetoclax.

• Venclyxto 10 mg film-coated tablets: Each film-coated tablet contains 10 mg of venetoclax.
• Venclyxto 50 mg film-coated tablets: Each film-coated tablet contains 50 mg of venetoclax.
• Venclyxto 100 mg film-coated tablets: Each film-coated tablet contains 100 mg of venetoclax.

The other ingredients are:

• In the tablet core: copovidone (K 28), polysorbate 80 (E433), colloidal anhydrous silica (E551), anhydrous calcium hydrogen phosphate (E341 (ii)), sodium stearyl fumarate.

In the film coating:

• Venclyxto 10 mg film-coated tablets: yellow iron oxide (E172), polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b).
• Venclyxto 50 mg film-coated tablets: yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172), polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b).
• Venclyxto 100 mg film-coated tablets: yellow iron oxide (E172), polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b).

Product Appearance and Package Contents

Venclyxto 10 mg film-coated tablet is pale yellow, round, 6 mm in diameter, marked with a V on one side and 10 on the other.

Venclyxto 50 mg film-coated tablet is beige, oblong, 14 mm long, marked with a V on one side and 50 on the other.

Venclyxto 100 mg film-coated tablet is pale yellow, oblong, 17.2 mm long, marked with a V on one side and 100 on the other.

Venclyxto tablets are available in blisters or bottles contained in cartons as follows:

Venclyxto 10 mg film-coated tablets:

• 10 tablets (5 blisters, each with 2 tablets)
• 14 tablets (7 blisters, each with 2 tablets)

Venclyxto 50 mg film-coated tablets:

• 5 tablets (5 blisters, each with 1 tablet)
• 7 tablets (7 blisters, each with 1 tablet)

Venclyxto 100 mg film-coated tablets:

• 7 tablets (7 blisters, each with 1 tablet)
• 14 tablets (7 blisters, each with 2 tablets)
• 112 (4 x 28) tablets (4 containers of 7 blisters, each with 4 tablets)
• 360 tablets (3 bottles of 120 tablets each)

Not all pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

AbbVie Deutschland GmbH & Co. KG

Knollstrasse

67061 Ludwigshafen

Germany

AbbVie S.r.l.

S.R. 148 Pontina, km 52 SNC

04011 Campoverde di Aprilia (Latina)

Italy

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Date of Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.

The leaflet can be found in all languages of the European Union/European Economic Area on the European Medicines Agency website.

To listen to this leaflet or request a copy in Braille, large print, or audio, contact the local representative of the marketing authorization holder.